Vericel (VCEL) Expected to Announce Earnings on Thursday

Vericel (NASDAQ:VCEL) is projected to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Vericel to post earnings of ($0.02) per share and revenue of $64.5680 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Vericel Price Performance

Shares of VCEL stock opened at $36.31 on Tuesday. The business has a 50-day moving average of $33.65 and a 200 day moving average of $37.77. The stock has a market capitalization of $1.83 billion, a PE ratio of 304.96 and a beta of 1.39. Vericel has a 1-year low of $29.24 and a 1-year high of $63.00.

Analyst Ratings Changes

Several equities analysts have commented on the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Vericel in a research report on Wednesday, October 8th. Zacks Research raised shares of Vericel from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. BTIG Research lowered shares of Vericel from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 17th. Truist Financial lowered their target price on shares of Vericel from $46.00 to $41.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. Finally, Canaccord Genuity Group reduced their price objective on Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Vericel currently has an average rating of “Moderate Buy” and an average target price of $58.40.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in VCEL. Osaic Holdings Inc. boosted its position in shares of Vericel by 13.7% in the second quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 353 shares during the period. Smartleaf Asset Management LLC grew its stake in Vericel by 178.4% during the second quarter. Smartleaf Asset Management LLC now owns 3,241 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 2,077 shares in the last quarter. Connecticut Wealth Management LLC purchased a new stake in Vericel in the 2nd quarter worth $201,000. Tower Research Capital LLC TRC boosted its holdings in shares of Vericel by 7,627.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,791 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 4,729 shares during the last quarter. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Vericel in the 2nd quarter worth about $225,000.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.